Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Third-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces First-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Unveils New Facility to Increase Vaccine Production Capacity
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the TD Cowen 45th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.